RECENT Deals & Transactions

---

July 2020

Conyers advises Agile Group Holdings Limited in connection with its issue of US$500 million 5.75% Senior Notes due 2025

July 2020

Conyers advises Ronshine China Holdings Limited in connection with its issue of an aggregate principal amount of US$160 million 7.35% senior notes due 2023

June 2020

Conyers advises NWD Finance (BVI) Limited in connection with its issue of an aggregate amount of US$200 million 5.25% Guaranteed Senior Perpetual Capital Securities

June 2020

Conyers advises Jiayuan International Group Limited in connection with its issue of an aggregate amount of US$120 million 11.75% senior notes due 2021

June 2020

Conyers advises NWD Finance (BVI) Limited in connection with its issue of an aggregate amount of US$650 million 5.25% Guaranteed Senior Perpetual Capital Securities

June 2020

Conyers Advises Digicel on its $US7 billion debt restructuring

June 2020

Conyers advises Ronshine China Holdings Limited in connection with its issue of an aggregate principal amount of US$250 million 7.35% senior notes due 2023

June 2020

Conyers advises the Carlyle Group on its acquisition of a 71.5% stake in Fortitude Group Holdings

June 2020

Conyers advises Fantasia Holdings Group Co., Limited in connection with the issue of senior notes

May 2020

Conyers advises GreyCastle Holdings Ltd. on its sale to Monument Re Limited

May 2020

Conyers advises Redco Properties Group Limited in connection with its offer to purchase for cash its outstanding US$310.4 million 11.0% senior notes due 2020

May 2020

Conyers advises Redco Properties Group Limited in connection with its issue of an aggregate principal amount of US$150 million 13.0% senior notes due 2023

May 2020

Conyers advises Li & Fung Limited in connection with its HK$7.2 billion privatisation by way of scheme of arrangement

May 2020

Conyers advises NWD (MTN) Limited in connection with its issue of an aggregate principal amount of US$600 million 4.5% guaranteed notes due 2030

May 2020

Conyers advises Kintor Pharmaceutical Limited in connection with its HK$1 billion IPO

---

Disclaimer: These publications are not intended to be a substitute for legal advice or a legal opinion. They deal in broad terms and are intended to merely provide as a brief overview and give general information.